Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CPS2 is a proteolysis-targeting chimera (PROTAC) composed of the Cdk2 binder J2, a derivative of the Cdk and Aurora kinase inhibitor JNJ-7706621 (Item No. 18494), connected to the cereblon inhibitor pomalidomide (Item No. 19877) by a linker region.1 It selectively degrades Cdk2 (IC50 = 24 nM) over seven additional CDKs at 500 nM but also degrades Aurora A kinase and Ikaros family zinc finger protein 1 (IKZF1) at 250 nM. CPS2 reduces Cdk2 levels and increases the percentage of cells expressing CD11b, a marker of differentiation, in primary acute myeloid lymphoma (AML) cells. It also decreases proliferation without reducing the viability of, as well as induces differentiation in, primary hematopoietic stem cells (HSCs).
WARNING This product is not for human or veterinary use.
1. Discovery of a first-